- Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data.
- It is estimated that the global NASH market could be worth $20 billion by 2027.
- Interim results from the phase 2 MOMENTUM study using pemvidutide for obesity are expected in Q4 of 2022; This will deal with 24-week interim data for weight loss.
- The global obesity treatment market will reach $15.6 billion by 2024.
For further details see:
Altimmune: Several Catalysts In 2 Large Market Indications This Year